Alzamend Neuro, Inc. (ALZN): Entry into a Material Definitive Agreement
Alzamend Neuro, Inc. (ALZN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On July 31, 2026 (the “ Execution Date ”), Alzamend Neuro, Inc., a Delaware corporation (the “ Company ”), entered into a Securities Purchase Agreement (the “ Agreement ”) with Ault Lending, LLC, a California limited liability
- Instrument
- Series D convertible preferred stock
- Gross proceeds
- $7.5 million
- Shares
- 7,500 Preferred Shares
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
A $25M preferred-stock financing can change the company’s capital structure and investor expectations. Traders will focus on dilution mechanics, conversion timing, and whether proceeds map to near-term catalysts.
Market read
Primary disclosure of a convertible preferred financing up to $25M aggregate, which can drive dilution and financing-risk repricing.
What to watch
Key trading drivers are missing from the excerpt, including conversion ratio/price, any beneficial ownership limits, investor participation rights, and whether proceeds fund specific clinical or regulatory milestones.
Background
The 8-K reports entry into a securities purchase agreement and an unregistered equity issuance, relying on exemptions from Securities Act registration.
Ticker impact
Alzamend Neuro entered a material definitive securities purchase agreement to issue up to 25,000 shares of Series D convertible preferred stock.
Likely near-term volatility tied to dilution expectations and conversion terms, with direction dependent on discount/beneficial conversion mechanics not shown in the excerpt.
The filing is a primary disclosure of a financing agreement size ($25M) and instrument type (convertible preferred). The excerpt does not include conversion price, discount, or investor rights, limiting precision on dilution magnitude and timing.
Market effects
Adds another small-cap biotech financing example, potentially reinforcing risk-off sentiment toward pre-commercial or development-stage issuers.
No clear regional spillover indicated by the excerpt.
Limited global relevance; this is company-specific private placement financing.
Counterpoint
If the preferred terms are favorable (e.g., limited conversion pressure, no aggressive reset), the deal could be viewed as runway extension rather than immediate dilution risk.
Key entities
- issuerAlzamend Neuro, Inc.
Company filing the 8-K and entering the securities purchase agreement.
- purchaserAult Lending, LLC
Counterparty purchasing up to 25,000 shares of Series D convertible preferred stock.
- securitySeries D Convertible Preferred Stock
Convertible preferred instrument issued under the agreement, priced at $1,000 per share with stated value $1,050.
